Regional Variation of Antimicrobial Use in Japan from 2013–2016, as Estimated by the Sales Data
-
- Kusama Yoshiki
- AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine Collaborative Chairs Emerging and Reemerging Infectious Diseases, National Center for Global Health and Medicine, Graduate School of Medicine, Tohoku University
-
- Ishikane Masahiro
- AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine Disease Control and Prevention Center, National Center for Global Health and Medicine
-
- Tanaka Chika
- AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine
-
- Kimura Yuki
- AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine
-
- Yumura Erina
- AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine
-
- Hayakawa Kayoko
- AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine Disease Control and Prevention Center, National Center for Global Health and Medicine
-
- Muraki Yuichi
- Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University
-
- Yamasaki Daisuke
- Department of Infection Control and Prevention, Mie University Hospital
-
- Tanabe Masaki
- Department of Infection Control and Prevention, Mie University Hospital
-
- Ohmagari Norio
- AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine Collaborative Chairs Emerging and Reemerging Infectious Diseases, National Center for Global Health and Medicine, Graduate School of Medicine, Tohoku University Disease Control and Prevention Center, National Center for Global Health and Medicine
この論文をさがす
抄録
<p>The National Action Plan on Antimicrobial Resistance in Japan aims to achieve a 50% reduction in the use of broad-spectrum oral antimicrobials (cephalosporins, macrolides, and quinolones) from 2013 to 2020. Based on the national sales data for antimicrobials, we estimated the regional antimicrobial use (AMU) from 2013–2016 and evaluated the differences in the use of broad-spectrum oral antimicrobials among three regions in which differences had been identified previously. The AMU was standardized based on the defined daily dose (DDD) and described as the DDDs/1,000 inhabitants/day (DID). Annual combined total oral and parenteral AMU during 2013–2016 was 14.9, 14.5, 14.7, and 14.6 DID, respectively. The change in mean ± standard deviation in the total AMU at the prefectural level was – 0.2 ± 0.8 DID. Among the 47 prefectures, decreasing trends were observed in 34, while in the remaining 13 prefectures increasing trends were recorded. In 2016, no significant differences in the mean usage of oral cephalosporins among the three regions were observed. The mean usage of oral macrolides in the eastern (4.1 DID) was significantly lower than that in the central region (4.7 DID) (p = 0.009) and the western (4.8 DID) (p = 0.002). The mean usage of oral quinolones in the western (3.2 DID) was significantly higher than that in the eastern (2.3 DID) (p < 0.001) and central (2.7 DID) (p = 0.001) regions. To determine appropriate targets for the implementation of antimicrobial stewardship for reducting the use of broad-spectrum oral antimicrobials, further studies are required to identify the reasons underlying these differences.</p>
収録刊行物
-
- Japanese Journal of Infectious Diseases
-
Japanese Journal of Infectious Diseases 72 (5), 326-329, 2019
国立感染症研究所 Japanese Journal of Infectious Diseases 編集委員会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390564227303849216
-
- NII論文ID
- 130007709126
-
- NII書誌ID
- AA1132885X
-
- ISSN
- 18842836
- 13446304
-
- NDL書誌ID
- 029987318
-
- PubMed
- 31061356
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可